RICHMAP
RICHMAP · Stock · OMX NORDIC EXCHANGE COPENHAGEN A/S ← Markets

NVO · OMX NORDIC EXCHANGE COPENHAGEN A/S

Novo Nordisk A/S

Pharmaceuticals
47.09
▲ 1.21 (2.64%)
Finnhub · 26. 6. 24. 오전 4:16 기준 (실시간~15분 지연)
차트 TradingView

재무 요약

Finnhub /stock/metric · 연간 기준 · 캐시 6h
PER (연간)
12.68
EPS (연간)
23.03
매출/주 (연간)
69.49
총이익률 (연간)
80.98%
영업이익률 (연간)
41.30%
순이익률 (연간)
데이터 없음
ROE
52.79%
배당수익률
3.90%
52주 최고
495.45
52주 최저
224.25
시총 (M)
1,298,604 DKKM
상장 주식수 (M)
3,390.13

▸ Finnhub /stock/profile2 · 캐시 24h · 모든 수치 API 원값 (RICHMAP 가공·추정 없음)

관련 뉴스

Finnhub /company-news · 최근 14일 · 캐시 30min
SeekingAlpha · 2026. 6. 23.

Healthcare's Quiet Comeback: Innovation, Obesity Drugs And New Opportunities

After lagging expectations during recent market volatility, the healthcare sector is showing signs of strength. TD Asset Management's Jacky He explains what's driving the sector’s rebound.

원문 보기 ↗ SeekingAlpha
SeekingAlpha · 2026. 6. 23.

Novo Nordisk: The Selloff Looks Like A Gift, And I'm Buying

Novo Nordisk upgraded to a 'Strong Buy': GLP-1 outlook, pricing headwinds, R&D, and valuation discount. Click here to read more on the NVO stock.

원문 보기 ↗ SeekingAlpha
Benzinga · 2026. 6. 23.

Novo Nordisk Stock Is Surging Monday: What's Driving The Action?

Novo-Nordisk shares are trading higher by more than 6% on Monday as GLP‑1 support initiatives aimed at improving access and persistence on therapy keep the weight-loss drug category in focus.

원문 보기 ↗ Benzinga
Benzinga · 2026. 6. 22.

CVS Pharmacy Announces New GLP-1 Offerings, Including Expanded Pharmacy Support And A New $49 MinuteClinic Virtual Visit That Connects Eligible Adults With Licensed Clinicians

As demand for GLP-1 medications continues to increase across the U.S., CVS Health® (NYSE:CVS) today announced a comprehensive approach to GLP-1 support spanning its more than 9,000 CVS Pharmacy® locat…

원문 보기 ↗ Benzinga
Benzinga · 2026. 6. 22.

Less Volume, More Premium: Post-Ozempic Economics Are Killing The Quantity Model

As millions take GLP-1 drugs, packaged food giants face declining volumes while protein brands and specialty grocers win.

원문 보기 ↗ Benzinga
Benzinga · 2026. 6. 18.

Hims & Hers Stock Jumps After Barclays Raises Price Target

Hims & Hers Health (NYSE: HIMS) shares are climbing after Barclays reiterated its bullish stance and lifted its price target from $29 to $39.

원문 보기 ↗ Benzinga
SeekingAlpha · 2026. 6. 18.

My Top 5 Dividend Picks For June

Keurig Dr Pepper, Novo Nordisk, Sonoco Products, Domino's Pizza, and Realty Income are top June dividend picks. Read more on KDP, NVO, SON, DPZ, O stocks here.

원문 보기 ↗ SeekingAlpha
Benzinga · 2026. 6. 17.

Novo Nordisk Data Breach: Hackers Claim To Have Stolen Drug Research, Trial Data And AI Models

Novo Nordisk investigates claims by cyber group FulcrumSec alleging a 1.3TB data theft after a failed $25M ransom demand. Read more.

원문 보기 ↗ Benzinga
SeekingAlpha · 2026. 6. 17.

Eli Lilly: Pharma With Unstoppable Momentum Targets Pain With Latest M&A Deal

Explore Eli Lilly and Company's surge, M&A strategy, and pipeline diversification beyond tirzepatide—plus 2030 revenue/valuation targets. Click for this LLY update.

원문 보기 ↗ SeekingAlpha
Benzinga · 2026. 6. 17.

Reported June 16, 2026: 'Hacking Group Claims Major Hack Of Novo Nordisk And Attempted $25 Million Extortion' - Reuters News

https://www.reuters.com/legal/government/hacking-group-claims-major-hack-novo-nordisk-attempted-25-million-extortion-2026-06-16/

원문 보기 ↗ Benzinga
SeekingAlpha · 2026. 6. 17.

Novo Nordisk: A Fallen Leader Trading At Fair Value, Not A Bargain

Novo Nordisk has lost GLP-1 leadership against Eli Lilly. Click here to read more about NVO stock and why it is a Hold.

원문 보기 ↗ SeekingAlpha
⚡ WHAT-IF ARENA · SIMULATION · 가상 · 실제 거래 아님

내 성향 트레이더로 도전

주어는 당신의 성향이지 이 종목이 아닙니다. 객관식 3개로 트레이더를 만들고, 6시간 동안 30분마다 가상 매매하는 걸 관전합니다. 하루 1번, 외부 개입 0.

⚠ 정보 제공 목적 · 투자 추천·자문 아님

본 페이지는 정보 제공 목적의 종목 정보 색인이며, 투자 권유·자문·중개가 아닙니다. RICHMAP은 증권사·금융투자업자가 아닙니다. 시세·재무·뉴스는 외부 데이터 소스(Finnhub 등)의 정보로 실시간성·정확성을 보증하지 않습니다. 모든 수치는 API 원값으로 RICHMAP의 가공·추정이 없으며, 조회 실패 시 "데이터 없음"으로 명시됩니다. 투자 판단과 그 결과 책임은 본인에게 있으며, 실제 거래는 정식 인가 증권사를 통해 본인 판단하에 진행하시기 바랍니다.